Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS)

Clinical Nephrology

Volumn 67, Issue 6, 2007, Pages 341-344

  Muso, E ^a   Mune, M ^b   Yorioka, N ^c   Nishizawa, Y ^d   Hirano, T ^e   Hattori, M ^f   Sugiyama, S ^g   Watanabe, T ^h   Kimura, K ⁱ   Yokoyama, H ^j   Sato, H ^k   Saito, T ^l  

^a Kitano Hospital   (Japan)

^b UNIVERSITY OF NAGASAKI   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

ⁱ ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j KANAZAWA UNIVERSITY   (Japan)

^k TOHOKU UNIVERSITY HOSPITAL   (Japan)

^l FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Focal segmental glomerulosclerosis; LDL apheresis; Long term outcome; Low density lipoprotein; Nephrotic syndrome; Retrospective survey

Indexed keywords

CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STEROID;

ADULT; APHERESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; EARLY INTERVENTION; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; JAPAN; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY;

EID: 34250204552     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp67341     Document Type: Article

References (8)

1. Hattori M, Chikamoto H, Akioka Y et al. A Combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis. 2003; 42: 1121-1130.
2. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996; 7: 56-63.
3. Muso E, Yashiro M, Matsushima M et al. Does LDL apheresis in steroid-resistant nephritic syndrome affect prognosis? Nephrol Dial Transplant. 1994; 9: 257-264.
4. Muso E, Mune M, Fujii Y et al for the Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Low-density lipoprotein apheresis therapy for steroid-resistant nephritic syndrome. Kidney Int. 1999; 56: S122-S125.
5. Muso E, Mune M, Fujii Y et al for the Kansai FGS LDL Apheresis Treatment (K-FLAT) Study Group. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron. 2001; 89: 408-415.
6. 2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. Atherosclerosis. 1998; 141: 99-105.
7. Sulowicz W Stompor T. LDL apheresis and immuno-adsorption: novel methods in the treatment of renal diseases refractory to conventional therapy. Nephrol Dial Transplant. 2003; 18 Suppl 5: v59-62.
8. Yokoyama K, Sakai S, Sigematsu T et al. LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. Clin Nephrol. 1998; 50: 1-7.